Two from UK join Caligor Rx in US

Will lead quality assurance and clinical trial supplies

Caligor Rx, a global clinical trial procurement company based in New York, US, has appointed Jess McKenna as head of quality assurance and customer relationships and Jacquelyn May as head of clinical trial supplies. The two women join Caligor Rx, as a team, after having spent five years working together for a UK supplier of clinical trial supplies.

McKenna has a first class degree in Health and Social Care from the Open University in the UK. She was most recently responsible for building a quality assurance department at a supplier of comparator drugs.

May is a registered nurse and joins Caligor Rx after five years in comparator procurement for worldwide clinical trials. She was previously a senior manager in the NHS in the UK.

You may also like

Regulatory

Diversis Capital acquires Caligor Rx

Caligor sources and distributes comparator drugs for clinical trials worldwide from the US and UK
Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway
Regulatory

American Chemistry Council's statement to Trump: make chemistry in America again

The Council has released a statement ahead of the President's State of the Union Address, asking for policies that unlock domestic production and address unfair foreign practices
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Regulatory

NICE approves Opzelura cream as first UK treatment for non-segmental vitiligo

Incyte Biosciences UK has secured NICE approval for Opzelura (ruxolitinib) cream, granting eligible NHS patients with non-segmental vitiligo access to the first and only approved therapy in England shown to support facial re-pigmentation
Regulatory

CDA-AMC rejects Leqembi reimbursement despite Health Canada approval

After expressing disappointment about a separate insomnia ruling, Eisai has criticised a draft decision by Canada's drug agency not to recommend public reimbursement of Leqembi for early Alzheimer's disease
Regulatory

Shield Therapeutics’ ACCRUFeR becomes first FDA-approved oral iron for children 10+

The FDA's approval for ACCRUFeR (ferric maltol) to treat iron deficiency in children aged 10 and older makes it the first and only prescription oral iron therapy specifically approved for this pediatric population
Subscribe now